The US Food and Drug Administration (FDA) has granted de novo authorisation to Roche’s cobas pro i 601 platform alongside the Ionify Gabapentin assay.
The regulatory decision expands the company’s diagnostic testing menu into therapeutic drug monitoring, bringing automated mass spectrometry systems into routine clinical laboratory settings.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Both the assay and the platform serve as components of Roche’s cobas mass spec solution. The technology integrates the analytical precision, high sensitivity, and specificity of mass spectrometry with an automated, standardised operational workflow, Roche stated.
Although mass spectrometry is widely utilised for clinical procedures that require sensitive and specific measurement, conventional practices have historically demanded specialised personnel and complex manual processing.
The new system is designed to transition these analytical capabilities away from dedicated reference facilities and into standard core laboratories.
Secured through the de novo pathway, the Ionify Gabapentin assay augments an existing US menu that features 17-Hydroxyprogesterone, 25-Hydroxy Vitamin D total, and estradiol steroid hormone tests.
Roche highlighted that it is continuing the development of further clinical mass spectrometry assays to enlarge its portfolio over time.
To support this progression, the firm will utilise a predetermined change control plan (PCCP) aimed at accelerating future menu additions while maintaining quality and safety protocols.
Under the authorised PCCP framework, up to 22 subsequent Ionify assays may be added to the cobas platform once applicable requirements are satisfied. None of these upcoming tests are currently available.
Roche Diagnostics North America president and CEO Dan Malarek said: “Some of the best diagnostic technologies are often very complex and, in the end, don’t actually reach patients.
“Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories.
“By automating and standardising this technology, we’re helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results.”
Earlier this month, the US FDA has cleared Roche’s respiratory pathogen testing panel to assist labs and clinicians in identifying the cause of infections as peak respiratory season begins.